Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB +8.08%44 Cash-to-Debt is 1.68 as of Mar. 2026, which is 68% above its 10-year median of 1.00. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review. Among 988 Drug Manufacturers companies, Quest Laboratories ranks better than 57.29% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Quest Laboratories's cash to debt ratio for the quarter that ended in Mar. 2026 was 1.68.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Quest Laboratoriescould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Quest Laboratories's Cash-to-Debt or its related term are showing as below:
NSE:QUESTLAB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14 Med: 1 Max: 1.68
Current: 1.68
During the past 6 years, Quest Laboratories's highest Cash to Debt Ratio was 1.68. The lowest was 0.14. And the median was 1.00.
NSE:QUESTLAB's Cash-to-Debt is ranked better than 57.29% of 988
companies
in the Drug Manufacturers industry
Industry Median: 1.005
vs NSE:QUESTLAB: 1.68
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Quest Laboratories Cash-to-Debt Related Terms
Quest Laboratories Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Cash-to-Debt Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a Cash-to-Debt of 1.68 as of Mar. 2026. This is 68% above median its historical median of 1.00. Over the past decade, Quest Laboratories' Cash-to-Debt has ranged from 0.14 to 1.68. According to the industry distribution chart, Quest Laboratories ranks #422 out of 988 companies in the Drug Manufacturers industry, placing it in the top 42.7%.
Is Quest Laboratories' Cash-to-Debt too high?
Quest Laboratories' current Cash-to-Debt of 1.68 is 68% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 1.68. The Drug Manufacturers industry median Cash-to-Debt is 1.01. Quest Laboratories' value of 1.68 is 67.2% above this industry median. Based on the distribution chart, Quest Laboratories ranks #422 out of 988 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Cash-to-Debt compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #422 out of 988 companies for Cash-to-Debt. This puts Quest Laboratories in the upper half of its industry. The industry median Cash-to-Debt is 1.01. Quest Laboratories' value of 1.68 is 67.2% above this benchmark. Historically, Quest Laboratories' own Cash-to-Debt has ranged from 0.14 to 1.68 over the past decade. While the company's 10-year median is 1.00 vs. the industry median of 1.01, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.01, based on 988 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Cash-to-Debt of 1.68 is 67.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Cash-to-Debt is 1.68, which is 68% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Cash-to-Debt of 1.68. The current Cash-to-Debt is 1.68, which is 68% above median its 10-year median of 1.00 and 67.2% above the Drug Manufacturers industry median of 1.01. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Cash-to-Debt is 1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
